- Home
- NDLS vs FBIO Comparison
NDLS vs FBIO Comparison
Compare NDLS & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- FBIO
- Stock Information
- Founded
- NDLS 1995
- FBIO 2006
- Country
- NDLS United States
- FBIO United States
- Employees
- NDLS N/A
- FBIO N/A
- Industry
- NDLS Restaurants
- FBIO Biotechnology: Pharmaceutical Preparations
- Sector
- NDLS Consumer Discretionary
- FBIO Health Care
- Exchange
- NDLS Nasdaq
- FBIO Nasdaq
- Market Cap
- NDLS 45.2M
- FBIO 49.1M
- IPO Year
- NDLS 2013
- FBIO N/A
- Fundamental
- Price
- NDLS $0.79
- FBIO $1.80
- Analyst Decision
- NDLS Strong Buy
- FBIO Strong Buy
- Analyst Count
- NDLS 2
- FBIO 2
- Target Price
- NDLS $3.00
- FBIO $21.00
- AVG Volume (30 Days)
- NDLS 153.2K
- FBIO 226.9K
- Earning Date
- NDLS 08-06-2025
- FBIO 08-12-2025
- Dividend Yield
- NDLS N/A
- FBIO N/A
- EPS Growth
- NDLS N/A
- FBIO N/A
- EPS
- NDLS N/A
- FBIO N/A
- Revenue
- NDLS $495,670,000.00
- FBIO $57,784,000.00
- Revenue This Year
- NDLS $5.37
- FBIO $51.59
- Revenue Next Year
- NDLS $0.68
- FBIO $44.74
- P/E Ratio
- NDLS N/A
- FBIO N/A
- Revenue Growth
- NDLS N/A
- FBIO N/A
- 52 Week Low
- NDLS $0.55
- FBIO $1.33
- 52 Week High
- NDLS $2.18
- FBIO $2.89
- Technical
- Relative Strength Index (RSI)
- NDLS 44.78
- FBIO 49.69
- Support Level
- NDLS $0.76
- FBIO $1.78
- Resistance Level
- NDLS $0.82
- FBIO $2.15
- Average True Range (ATR)
- NDLS 0.06
- FBIO 0.10
- MACD
- NDLS 0.00
- FBIO -0.02
- Stochastic Oscillator
- NDLS 25.00
- FBIO 18.92
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.